Free Trial

Caribou Biosciences (CRBU) Competitors

Caribou Biosciences logo
$2.82 +0.19 (+7.22%)
Closing price 04:00 PM Eastern
Extended Trading
$2.87 +0.05 (+1.77%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRBU vs. OCS, ORKA, BGM, MNMD, VALN, PROK, ANAB, KURA, AVBP, and PHAT

Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Oculis (OCS), Oruka Therapeutics (ORKA), BGM Group (BGM), Mind Medicine (MindMed) (MNMD), Valneva (VALN), ProKidney (PROK), AnaptysBio (ANAB), Kura Oncology (KURA), ArriVent BioPharma (AVBP), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.

Caribou Biosciences vs. Its Competitors

Caribou Biosciences (NASDAQ:CRBU) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Oculis had 5 more articles in the media than Caribou Biosciences. MarketBeat recorded 7 mentions for Oculis and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.17 beat Oculis' score of 0.53 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Caribou Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oculis
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Caribou Biosciences presently has a consensus price target of $6.67, suggesting a potential upside of 136.41%. Oculis has a consensus price target of $41.00, suggesting a potential upside of 87.90%. Given Caribou Biosciences' higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Oculis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Oculis
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Caribou Biosciences has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oculis has lower revenue, but higher earnings than Caribou Biosciences. Oculis is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caribou Biosciences$9.99M26.29-$149.10M-$1.78-1.58
Oculis$780K1,221.36-$97.43M-$2.67-8.17

Caribou Biosciences has a net margin of -1,800.93% compared to Oculis' net margin of -13,958.12%. Caribou Biosciences' return on equity of -62.35% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Caribou Biosciences-1,800.93% -62.35% -49.65%
Oculis -13,958.12%-90.31%-67.85%

Summary

Caribou Biosciences beats Oculis on 10 of the 15 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRBU vs. The Competition

MetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$244.91M$3.48B$6.17B$10.68B
Dividend YieldN/A2.27%5.70%4.84%
P/E RatioN/A23.3929.4727.36
Price / Sales26.29485.50589.24132.03
Price / CashN/A45.2825.8230.35
Price / Book1.0110.6112.526.69
Net Income-$149.10M-$52.56M$3.32B$276.59M
7 Day Performance18.49%4.94%2.43%0.97%
1 Month Performance66.86%16.10%8.78%3.95%
1 Year Performance41.00%14.51%62.11%36.40%

Caribou Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRBU
Caribou Biosciences
2.5605 of 5 stars
$2.82
+7.2%
$6.67
+136.4%
+31.5%$244.91M$9.99M0.00100Gap Up
OCS
Oculis
2.4466 of 5 stars
$21.00
-0.4%
$41.00
+95.2%
+55.0%$920.84M$780K-7.872Short Interest ↑
ORKA
Oruka Therapeutics
2.8153 of 5 stars
$25.50
+4.1%
$41.80
+63.9%
-7.7%$917.17MN/A-9.07N/AAnalyst Downgrade
BGM
BGM Group
0.2863 of 5 stars
$9.49
+1.7%
N/A+19.7%$907.08M$25.10M0.00298Short Interest ↑
Gap Up
MNMD
Mind Medicine (MindMed)
3.4026 of 5 stars
$12.25
+3.7%
$27.83
+127.2%
+106.5%$898.60MN/A-8.0140Gap Up
VALN
Valneva
2.9617 of 5 stars
$10.50
+1.3%
$15.00
+42.9%
+70.7%$891.07M$183.52M-10.71700Short Interest ↓
PROK
ProKidney
2.5672 of 5 stars
$2.99
-1.0%
$6.25
+109.0%
+50.8%$888.73M$80K-5.253News Coverage
ANAB
AnaptysBio
2.7275 of 5 stars
$32.46
+3.5%
$52.00
+60.2%
-1.0%$878.27M$91.28M-7.25100Analyst Revision
KURA
Kura Oncology
4.2841 of 5 stars
$9.93
+0.8%
$24.67
+148.4%
-45.3%$854.95M$53.88M-4.39130News Coverage
Analyst Forecast
AVBP
ArriVent BioPharma
1.4862 of 5 stars
$20.90
+0.2%
$39.14
+87.3%
-33.1%$846.27MN/A-5.2040
PHAT
Phathom Pharmaceuticals
3.1038 of 5 stars
$12.53
+6.0%
$17.50
+39.7%
-19.4%$838.55M$55.25M-2.65110News Coverage
Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:CRBU) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners